Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.53 |
| ▸ | BACE1 | P56817 | 13/20 | 0.47 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.44 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6003692 | 0.82 | CYP19A1 (0.57) | CYP19A1BACE1BACE2CTSDHSD11B1 | |
| SCHEMBL11078445 | 0.78 | CYP19A1 (0.71) | CYP19A1BACE1BACE2CTSD | |
| SCHEMBL11079440 | 0.77 | CYP19A1 (0.55) | CYP19A1BACE1BACE2CTSD | |
| SCHEMBL4190208 | 0.72 | CYP19A1 (0.62) | CYP19A1BACE1 | |
| SCHEMBL4181298 | 0.70 | CYP19A1 (0.59) | CYP19A1BACE1 | |
| SCHEMBL6002297 | 0.70 | CYP19A1 (0.72) | CYP19A1BACE1 | |
| SCHEMBL11076987 | 0.70 | CYP19A1 (0.72) | CYP19A1BACE1BACE2CTSD | |
| SCHEMBL4771129 | 0.69 | CYP19A1 (0.58) | CYP19A1 | |
| SCHEMBL14101938 | 0.69 | KDM1A (0.40) | BACE1BACE2NSD2HSD11B1 | |
| SCHEMBL4190618 | 0.68 | CYP19A1 (0.57) | CYP19A1BACE1BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060223875-A1 | Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes | DOV PHARMACEUTICAL, INC. | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223875-A1 | Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes | HTR1B, SLC6A3, CYP1B1 | CYP19A1 461/4885BACE1 469/4885BACE2 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.